The Frequency of BCR-ABL1 Fusion Transcripts in Iranian Patients with Three Different Types of Leukemia

Different BCR-ABL fusion transcripts occur more or less frequently, in three different types of leukemia
This study was done to determine the frequencies of BCR-ABL fusion transcripts in leukemia patients from Iran.
This experimental study was carried out from 2001 to 2015 in Pasteur Institute of Iran. The leukemia patients containing 348 chronic myeloid leukemia (CML), 72 acute lymphoblastic leukemia (ALL), and 34 acute myeloid leukemia (AML) were studied. Total RNA was extracted from peripheral blood samples and analyzed by multiplex RT-PCR in 486 leukemia patients to detect different types of BCR-ABL transcripts. Fisher’s exact test was used in comparing qualitative variables in the case control study. Associations with a P value The BCR-ABL transcript frequencies for CML, ALL and AML patients were 92.0%, 12.5% and 14.7% respectively for all transcripts. The majority of CML patients with positive BCR-ABL expressed one of the p210BCR-ABL transcripts (86.6%) while the remaining showed other transcripts (p190BCR-ABL 25 (7.8%)) and p230BCR-ABL 2 (0.6%)). The rate of co-expression of the p190/p210 transcripts were 16 (5%). In other types of leukemia patients the rates of expression of those transcripts were different.
For the first time, we reported co-expression of p210/p190 which may be caused by alternative splicing in Iranian patients. This study we showed no significant correlation between BCR-ABL1 variants, age, sex type, and WBC count of studied leukemia patients.